Given the increasing importance of immunotherapy for the management of patients with SCLC and that WEE1 inhibitors are already in clinical trials, combining a WEE1 inhibitor with anti-PD-L1 blockade may offer a particularly attractive strategy for the treatment of SCLC. Here, CD274 is linked to small cell lung carcinoma.